Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/2025
Título : Biological treatments in Behçet's disease: beyond anti-TNF therapy.
Autor : Caso, Francesco
Costa, Luisa
Rigante, Donato
Lucherini, Orso Maria
Caso, Paolo
Bascherini, Vittoria
Frediani, Bruno
Cimaz, Rolando
Marrani, Edoardo
Nieves-Martín, Laura
Atteno, Mariangela
Raffaele, Carmela G L
Tarantino, Giusyda
Galeazzi, Mauro
Punzi, Leonardo
Cantarini, Luca
Filiación: [Caso,F; Lucherini,OM; Bascherini,V; Frediani,B; Nieves-Martin,L; Galeaxxi,M; Cantarini,L] Interdepartmental Research Center of Systemic Autoimmune and Autoinflammatory Diseases, Rheumatology Unit, Policlinico Le Scotte, University of Siena, Siena, Italy. [Caso,F; Punzi,L] Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy. [Costa,L; Atteno, M] Rheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy. [Rigante,D; Raffaele,CGL; Tarantino,G] Institute of Pediatrics, Cattolica Sacro Cuore University, Rome, Italy. [Caso,P] La Sapienza University, Rome, Italy. [Cimaz,R; Marrani,E] Department of Pediatrics, Rheumatology Unit, Anna Meyer Children’s Hospital and University of Florence, Florence, Italy. [Nieves-Martín,L] Rheumatology Service, Hospital Regional Universitario Carlos Haya, University of Màlaga, Màlaga, Spain.
Palabras clave : Anticuerpos monoclonales humanizados
Síndrome de behçet
Interleucina 1
Interleucina-1beta
Interleucina-6
Factor necrosis tumoral alfa
MeSH: Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Globulins::Serum Globulins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Globulins::Serum Globulins::Immunoglobulins::Antibodies::Antibodies, Monoclonal
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Globulins::Serum Globulins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Murine-Derived
Medical Subject Headings::Diseases::Skin and Connective Tissue Diseases::Skin Diseases::Skin Diseases, Vascular::Behcet Syndrome
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Chemicals and Drugs::Biological Factors::Intercellular Signaling Peptides and Proteins::Cytokines::Interleukins::Interleukin-1
Medical Subject Headings::Chemicals and Drugs::Biological Factors::Intercellular Signaling Peptides and Proteins::Cytokines::Interleukins::Interleukin-1::Interleukin-1beta
Medical Subject Headings::Chemicals and Drugs::Biological Factors::Intercellular Signaling Peptides and Proteins::Cytokines::Interleukins::Interleukin-6
Medical Subject Headings::Chemicals and Drugs::Biological Factors::Intercellular Signaling Peptides and Proteins::Tumor Necrosis Factors::Tumor Necrosis Factor-alpha
Fecha de publicación : 30-Jun-2014
Editorial : Hindawi Publishing Corporation
Cita Bibliográfica: Caso F, Costa L, Rigante D, Lucherini OM, Caso P, Bascherini V, et al. Biological treatments in Behçet's disease: beyond anti-TNF therapy. Mediators Inflamm.; 2014:107421
Abstract: Behçet's disease (BD) is universally recognized as a multisystemic inflammatory disease of unknown etiology with chronic course and unpredictable exacerbations: its clinical spectrum varies from pure vasculitic manifestations with thrombotic complications to protean inflammatory involvement of multiple organs and tissues. Treatment has been revolutionized by the progressed knowledge in the pathogenetic mechanisms of BD, involving dysfunction and oversecretion of multiple proinflammatory molecules, chiefly tumor necrosis factor- (TNF-) α, interleukin- (IL-) 1β, and IL-6. However, although biological treatment with anti-TNF-α agents has been largely demonstrated to be effective in BD, not all patients are definite responders, and this beneficial response might drop off over time. Therefore, additional therapies for a subset of refractory patients with BD are inevitably needed. Different agents targeting various cytokines and their receptors or cell surface molecules have been studied: the IL-1 receptor has been targeted by anakinra, the IL-1 by canakinumab and gevokizumab, the IL-6 receptor by tocilizumab, the IL12/23 receptor by ustekinumab, and the B-lymphocyte antigen CD-20 by rituximab. The aim of this review is to summarize all current experiences and the most recent evidence regarding these novel approaches with biological drugs other than TNF-α blockers in BD, providing a valuable addition to the actually available therapeutic armamentarium.
Descripción : Journal Article; Review;
URI: http://hdl.handle.net/10668/2025
Versión del editor : http://www.hindawi.com/journals/mi/2014/107421/abs/
DOI: 10.1155/2014/107421
ISSN : 1466-1861 (Online)
0962-9351 (Print)
Appears in Collections:01- Artículos - Hospital Regional de Málaga

Files in This Item:
File Description SizeFormat 
CasoF_BiologicalTreatment.pdfArtículo publicado2,16 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons